Cargando…

Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer capability, here we investigated the potential involvement o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yu-Cheng, Chiang, Yi-Hao, Hsu, Kate, Chuang, Chih-Kuang, Kao, Chen-Wei, Chang, Yi-Fang, Chang, Ming-Chih, Lim, Ken-Hong, Cheng, Hung-I, Hsu, Yen-Ning, Chen, Caleb G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595379/ https://www.ncbi.nlm.nih.gov/pubmed/34785653 http://dx.doi.org/10.1038/s41408-021-00572-7

Ejemplares similares

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
por: Chang, Ming-Chin, et al.
Publicado: (2019)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
por: Su, Yi‐Jiun, et al.
Publicado: (2022)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
por: Sun, Xiaoyan, et al.
Publicado: (2016)

IGF-IR determines the fates of BCR/ABL leukemia
por: Xie, Jingjing, et al.
Publicado: (2015)

Higher Hospitalization Rate for Lower Airway Infection in Transfusion-Naïve Thalassemia Children
por: Tsai, Ti-An, et al.
Publicado: (2020)

Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014)

Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia
por: Cabanas, Hélène, et al.
Publicado: (2018)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
por: Mariotti, Benedetta, et al.
Publicado: (2019)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia
por: Baer, Constance, et al.
Publicado: (2021)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Loss of Gadd45b accelerates BCR-ABL-driven CML
por: Sha, Xiaojin, et al.
Publicado: (2018)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case
por: Al-Achkar, Walid, et al.
Publicado: (2014)

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
por: Samanta, A, et al.
Publicado: (2011)

Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients
por: Nandagopalan, S. Rajashree, et al.
Publicado: (2016)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

p210(BCR‐ABL1)‐ Chronic myeloid leukemia presents with monocytosis
por: Wang, Xiaofei, et al.
Publicado: (2020)

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
por: Yu, Chuanjiang, et al.
Publicado: (2020)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Expression of chronic myeloid leukemia oncogenes BCR-ABL (P210) and BCR-ABL (T315I) affect cellular and humoral innate immunity in Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

8-Hydroxydaidzein, an Isoflavone from Fermented Soybean, Induces Autophagy, Apoptosis, Differentiation, and Degradation of Oncoprotein BCR-ABL in K562 Cells
por: Wu, Pei-Shan, et al.
Publicado: (2020)

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID
por: Zhang, Ping, et al.
Publicado: (2022)

Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia
Publicado: (1989)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

NPM1 Mutated, BCR-ABL1 Positive Myeloid Neoplasms: Review of the Literature
por: Catalano, Gianfranco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vvedngf424tolut1a98i2rvh2g